Medical device company DexCom (NASDAQ: DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 billion. The company expects the full year’s revenue to be around $5.22 billion, close to analysts’ estimates. Its non-GAAP profit of $0.70 per share was 15.1% above analysts’ consensus estimates.
Is now the time to buy DXCM? Find out in our full research report (it’s free for active Edge members).
DexCom (DXCM) Q2 CY2026 Highlights:
- Revenue: $1.31 billion vs analyst estimates of $1.29 billion (13.1% year-on-year growth, 1.4% beat)
- Adjusted EPS: $0.70 vs analyst estimates of $0.61 (15.1% beat)
- Adjusted EBITDA: $421.3 million vs analyst estimates of $390.7 million (32.2% margin, 7.8% beat)
- The company slightly lifted its revenue guidance for the full year to $5.22 billion at the midpoint from $5.21 billion
- Operating Margin: 24.3%, up from 18.4% in the same quarter last year
- Organic Revenue rose 12% year on year (beat)
- Market Capitalization: $28.76 billion
StockStory’s Take
DexCom’s second quarter was marked by robust revenue growth and a significant margin expansion, with management attributing performance to strong global demand for its continuous glucose monitoring (CGM) solutions and broadening patient access. CEO Jake Leach cited “solid execution across the business,” including multiple product launches and continued share gains in core markets. International momentum, particularly in markets where reimbursement recently expanded, also played a key role. Operational improvements, such as manufacturing efficiencies and a successful rollout of the G7 15-day system, further contributed to the company’s margin gains and customer satisfaction.
Looking forward, management’s outlook is shaped by efforts to secure broader reimbursement for people with type 2 diabetes not using insulin, ongoing product innovation, and international expansion. Leach emphasized the potential impact of data from the CONNECT trial, which has been submitted to CMS for coverage consideration, stating, “We believe these results only strengthen the case for reimbursement.” The company is also preparing for the commercial launch of its Ireland manufacturing facility, investing in digital health capabilities, and integrating Nutrisense to enhance personalized care and engagement. These initiatives are expected to support sustained revenue growth and margin improvement.
Key Insights from Management’s Remarks
DexCom’s management credited the quarter’s results to growing adoption of CGM technology, improved operational efficiency, and new product launches, while emphasizing ongoing investments in digital tools and global market access.
-
Broader type 2 diabetes access: Management highlighted expanded commercial reimbursement for type 2 diabetes patients not on insulin, now covering over 7 million people in the U.S. CEO Jake Leach described this as a “great start” but reiterated the company’s ambition for global coverage, noting ongoing advocacy and submissions to CMS for further expansion.
-
CONNECT trial impact: The CONNECT clinical trial demonstrated a 1.6% reduction in A1C for DexCom CGM users in the type 2 non-insulin segment. Leach explained that the data’s strength—particularly high engagement and improved health outcomes—could drive further reimbursement and clinical adoption, especially when combined with real-world evidence showing reduced hospitalizations and complications.
-
15-day G7 system adoption: The G7 15-day CGM system is being rapidly adopted in the U.S., with management expecting nearly half of the domestic customer base to convert by year-end. Positive customer feedback and improved net promoter scores were cited as drivers of uptake. International expansion is underway, with Canada recently approving the 15-day system and additional markets targeted.
-
Operational leverage and margin gains: CFO Jereme Sylvain pointed to ongoing manufacturing efficiencies, supply chain optimizations, and the margin benefit from the G7 15-day system as key contributors to operating margin improvement. The company is also investing in ramping up its new Ireland facility, which is expected to create some near-term cost headwinds but lay the foundation for future growth.
-
Digital health and Nutrisense acquisition: DexCom completed its acquisition of Nutrisense, a platform focused on delivering nutrition insights based on CGM data. Management views this integration as a way to enhance user engagement and deliver more personalized care, with early signs of strong customer uptake and engagement.
Drivers of Future Performance
DexCom expects continued growth to be driven by expanded insurance coverage, international market penetration, and product innovation, though new manufacturing investments and regulatory timelines may influence the pace of progress.
-
CMS coverage expansion: Management is focused on achieving Medicare reimbursement for type 2 diabetes patients not on insulin. The CONNECT trial data has been submitted to CMS, with a decision expected by year-end and potential implementation in 2027. This coverage could significantly increase DexCom’s addressable market and drive long-term growth.
-
Product pipeline and manufacturing scale: DexCom is advancing development of new CGM platforms, including the G8 sensor and expanded multi-analyte capabilities. The new Ireland manufacturing facility will support global supply, but management noted near-term margin impact as hiring and ramp-up costs are absorbed ahead of commercial production.
-
Digital platforms and engagement: Investment in digital health tools, like the redesigned Stello app and the integration of Nutrisense, is expected to boost patient engagement and retention, especially among people with prediabetes and type 2 diabetes. Management believes these enhancements will support broader adoption and recurring usage across domestic and international markets.
Catalysts in Upcoming Quarters
In the coming quarters, our analyst team will monitor (1) the outcome of the CMS decision on coverage for type 2 diabetes patients not on insulin, (2) the pace and impact of G7 15-day system adoption in the U.S. and new international approvals, and (3) the operational ramp-up of the Ireland manufacturing facility. Additional focus will be placed on how integration of Nutrisense and digital health initiatives affect patient engagement and recurring revenue.
DexCom currently trades at $80.50, up from $74.54 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
